Log in
Register
Searchsyrup hybrid application [Regulatives / Guidelines]
Dear Aga,
» If we would go 10.3 - how we should prove equivalence with this tricky syrup? Bioequivalence - because the product is not pharmaceutically equivalent? or can we somehow prove pharmaceutical equivalence with double dose vs single dose? Is it possible?
I really meant what I said - this can be perceived completely heterogeneously between countries. You may get as many answers as there are agencies. Therefore, take scientific advices (pl.) and try to rely on that. They may need in vivo studies, or they may not. They may need ther. equivalence in stead of bioequivalence, or they may not. They may let you get away with some in vitro work, or they may not. They may accept a bunch of literature, or they may not. They may be totally paranoid and conservative because you are doing something related to children, or they may not.
Request scientific advice. Even if there is no budget and no time.
Note also that BE does not have the same definition in EU and US.
» If we would go 10.3 - how we should prove equivalence with this tricky syrup? Bioequivalence - because the product is not pharmaceutically equivalent? or can we somehow prove pharmaceutical equivalence with double dose vs single dose? Is it possible?
I really meant what I said - this can be perceived completely heterogeneously between countries. You may get as many answers as there are agencies. Therefore, take scientific advices (pl.) and try to rely on that. They may need in vivo studies, or they may not. They may need ther. equivalence in stead of bioequivalence, or they may not. They may let you get away with some in vitro work, or they may not. They may accept a bunch of literature, or they may not. They may be totally paranoid and conservative because you are doing something related to children, or they may not.
Request scientific advice. Even if there is no budget and no time.
Note also that BE does not have the same definition in EU and US.
—
Best regards,
ElMaestro
"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
if (3) 4 Best regards,
ElMaestro
"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Complete thread:
- syrup hybrid application - Aga, 2017-09-06 13:52 [Regulatives / Guidelines]
![[Mix]](http://static.bebac.at/img/mix.png "Open in mix view")
- syrup hybrid application - ElMaestro, 2017-09-06 14:44
- syrup hybrid application - Aga, 2017-09-07 13:52
- syrup hybrid application - ElMaestro, 2017-09-07 14:10
- syrup hybrid application - Aga, 2017-09-07 14:54
- syrup hybrid application - ElMaestro, 2017-09-07 14:10
- syrup hybrid application - Aga, 2017-09-07 13:52
- syrup hybrid application - ElMaestro, 2017-09-06 14:44
Admin contact
